Sage, Biogen

Sage rejects Biogen's $469 million takeover offer, says offer undervalues company
Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it "significantly undervalues" the company and does not serve shareholders' best interests.
Sage Therapeutics Rejects Biogen’s $469M Offer, Citing Undervaluation
Sage Therapeutics announced its boards unanimous rejection of Biogens $469 million acquisition offer, stating the proposal significantly undervalues the company and does not align with shareholder interests.
Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen Inc.
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the embattled biotech at just $469 million.
No deal: Sage rejects Biogen's buyout offer, scouts for strategic alternatives
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. | The company's board of directors unanimously rejected partner Biogen's $469 million buyout proposal,
Sage Therapeutics Explores Alternatives, Rejects Biogen's Proposal, Stock Up
(RTTNews) - Sage Therapeutics, Inc. (SAGE) Monday announced that its Board of Directors has initiated a strategic review process aimed at maximizing shareholder value, involving a wide range of options, such as potential strategic transactions, business combinations, or the sale of the company.
Sage Sues Partner Biogen After Unsolicited Takeover Offer
Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital Markets.
Sage rejects Biogen's $469 million takeover offer
Sage Therapeutics said on Monday that its board has unanimously rejected the takeover offer it received from Biogen. The company said Biogen's offer to buy all outstanding shares of Sage that it does not already own for $7.
BioPharma Dive5h
Sage rebuffs Biogen bid to take it over
Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...
Sage Group falls Monday, underperforms market
Sage Group PLC SGE shares inched down 0.34% to £13.26 Monday, on what proved to be an all-around favorable trading session ...
Pierre Sage sacked as Lyon manager, Paulo Fonseca favourite to succeed
According to a report from L’Équipe, Olympique Lyonnais have decided to sack Pierre Sage from his role as manager following ...
FiercePharma6d
Sage sues Biogen as analyst detects little interest in buyout at original offer price
Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...
TaxBandits Strengthens Its Partnership with Sage Intacct for Another Successful Season of 1099 E-filing
ROCK HILL, SC / ACCESS Newswire / January 27, 2025 / With the January 31, 2025, deadline for 1099 filing approaching, TaxBandits, an authorized ...
‘Recalibrated’ Sage Hill girls basketball races past Portola to extend winning streak
Amalia Holguin, Addison Uphoff and Kamdyn Klamberg combine for 47 points as Sage Hill wins its sixth straight game.
TheGamer on MSN4d
Guide To Playing Sage In PvP In FFXIV
While you don't have all the multitude of skills Sage has in PvE, the core concept of the job is maintained in PvP. Although ...
Hosted on MSN3d
Sage Group Undertakes Share Buyback to Boost Shareholder Value
Sage Group plc ( ($GB:SGE) ) has issued an update. Sage Group plc has repurchased 389,944 of its ordinary shares as part of a share buyback ...